Misha Denham, DO
Endocrinology, Diabetes & Metabolism · Coral Gables, FLNPI 1689659096
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $590,978 of the $673,302 with a category attached, or 87.8%. Lilly USA, LLC accounts for 66.6% of it on its own, with 54 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,519 payments — averaging $443.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$448K
- Novo Nordisk$169K
- Mannkind Corporation$23K
- Merck$17K
- Verity Pharmaceuticals Inc.$8K
- Corcept Therapeutics$3K
- plus $7K from 49 others
What the payments were for
- Consulting fees$23,0993%
- Speaking & faculty fees$590,97888%
- Travel & lodging$37,9836%
- Food & beverage$21,0113%
- Education$2310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$673,302 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 260 | $423,506 |
| MounjaroTirzepatide | 287 | $412,429 |
| JardianceEmpagliflozin | 197 | $244,746 |
| Tresiba Flextouch U-100Insulin Degludec | 197 | $183,254 |
| RybelsusSemaglutide | 58 | $148,228 |
| TrulicityDulaglutide | 64 | $124,882 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 92 | $108,180 |
| CreonLipase/Protease/Amylase | 25 | $101,926 |
| EliquisApixaban | 72 | $85,896 |
| FarxigaDapagliflozin Propanediol | 58 | $78,251 |
| VascepaIcosapent Ethyl | 104 | $66,348 |
| TradjentaLinagliptin | 46 | $65,247 |
| JanuviaSitagliptin Phosphate | 44 | $59,001 |
| LinzessLinaclotide | 43 | $57,381 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $37,132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Tresiba, Fiasp | $168,791 | $594,427351 claims |
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog | $448,253 | $556,770395 claims |
| Boehringer IngelheimJardiance, Tradjenta | $557 | $309,993243 claims |
| MerckJanumet Xr, Januvia, Janumet | $16,751 | $193,649163 claims |
| AbbVieCreon, Linzess, Synthroid | $437 | $188,179327 claims |
| AstraZenecaFarxiga | $289 | $78,25158 claims |
| Johnson & JohnsonXarelto, Invokana | $1,531 | $58,88340 claims |
| Antares Pharma, Inc.Xyosted | $229 | $33,09132 claims |
| AmgenProlia | $264 | $24,72414 claims |
| NovartisEntresto | $42 | $18,71112 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $109 | $7,133629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Coral Gables
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
- Lee MetchickDeland$728K
- Barry HorowitzWest Palm Beach$628K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.